Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on transforming care for patients with autoimmune and inflammatory diseases, has announced the presentation of new translational data on its receptor-interacting protein kinase 2 (RIPK2) scaffolding inhibitor, OD-07656, at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia, scheduled for October 25-30, 2024.
RIPK2 activation in innate immune cells is associated with several aspects of inflammatory bowel disease (IBD) pathogenesis, serving as a key signal transducer and amplifier of cytokine production. The upcoming presentation will explore the anti-inflammatory and anti-fibrotic effects of inhibiting RIPK2 scaffolding, a proprietary gene signature indicative of RIPK2 activation, the role of RIPK2 in resistance to standard therapies, and the additive benefits of combining RIPK2 inhibition with standard treatments.
“Odyssey’s presentation underscores our commitment to advancing potentially transformative therapies for inflammatory diseases,” stated Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics. “At this year’s ACG, we will present additional data supporting the monotherapy potential of our RIPK2 product candidate, as well as its capacity to enhance responses and tackle treatment resistance when used in combination with standard therapies. We are excited about the prospects of an innate immune-targeted treatment for patients with IBD and look forward to sharing our findings with researchers and patients alike.
